Thermo Fisher Scientific Inc. (NYSE:TMO) Declares Quarterly Dividend of $0.39

Thermo Fisher Scientific Inc. (NYSE:TMO) announced a quarterly dividend on Thursday, November 7th,RTT News reports. Shareholders of record on Friday, December 13th will be given a dividend of 0.39 per share by the medical research company on Wednesday, January 15th. This represents a $1.56 annualized dividend and a yield of 0.28%.

Thermo Fisher Scientific has increased its dividend payment by an average of 16.7% per year over the last three years. Thermo Fisher Scientific has a payout ratio of 6.6% meaning its dividend is sufficiently covered by earnings. Analysts expect Thermo Fisher Scientific to earn $23.47 per share next year, which means the company should continue to be able to cover its $1.56 annual dividend with an expected future payout ratio of 6.6%.

Thermo Fisher Scientific Trading Down 0.7 %

Thermo Fisher Scientific stock opened at $555.89 on Friday. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific has a 12 month low of $437.26 and a 12 month high of $627.88. The stock’s 50 day simple moving average is $596.33 and its two-hundred day simple moving average is $583.80. The firm has a market cap of $212.63 billion, a PE ratio of 34.85, a P/E/G ratio of 3.70 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The business had revenue of $10.60 billion for the quarter, compared to analyst estimates of $10.63 billion. During the same quarter in the prior year, the firm posted $5.69 EPS. The business’s quarterly revenue was up .2% compared to the same quarter last year. Analysts anticipate that Thermo Fisher Scientific will post 21.69 earnings per share for the current year.

Wall Street Analyst Weigh In

TMO has been the topic of several recent research reports. Stephens started coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, October 1st. They set an “overweight” rating and a $680.00 target price on the stock. Bernstein Bank lifted their price target on Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a report on Tuesday, October 22nd. Evercore ISI reduced their price target on Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. UBS Group upgraded shares of Thermo Fisher Scientific to a “strong-buy” rating in a report on Monday, September 16th. Finally, Morgan Stanley boosted their price objective on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the company an “overweight” rating in a report on Friday, September 20th. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $649.33.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the completion of the transaction, the chief executive officer now directly owns 121,192 shares of the company’s stock, valued at approximately $67,175,513.68. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $554.29, for a total value of $5,542,900.00. Following the completion of the transaction, the chief executive officer now directly owns 121,192 shares of the company’s stock, valued at $67,175,513.68. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Marc N. Casper sold 5,850 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $557.89, for a total value of $3,263,656.50. Following the completion of the transaction, the chief executive officer now directly owns 121,192 shares of the company’s stock, valued at $67,611,804.88. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 18,150 shares of company stock valued at $10,094,925. 0.34% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.